Nothing Special   »   [go: up one dir, main page]

Su et al., 2019 - Google Patents

Reviewing HIV-1 Gag mutations in protease inhibitors resistance: insights for possible novel Gag inhibitor designs

Su et al., 2019

View HTML
Document ID
791884333345606161
Author
Su C
Koh D
Gan S
Publication year
Publication venue
Molecules

External Links

Snippet

HIV protease inhibitors against the viral protease are often hampered by drug resistance mutations in protease and in the viral substrate Gag. To overcome this drug resistance and inhibit viral maturation, targeting Gag alongside protease rather than targeting protease …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/01—Input arrangements or combined input and output arrangements for interaction between user and computer

Similar Documents

Publication Publication Date Title
Calligari et al. Molecular investigation of SARS–CoV-2 proteins and their interactions with antiviral drugs
Kumar et al. Possible link between higher transmissibility of alpha, kappa and delta variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity
Ortega et al. Class AG protein-coupled receptor antagonist famotidine as a therapeutic alternative against SARS-CoV2: an in silico analysis
Agost-Beltrán et al. Advances in the development of SARS-CoV-2 Mpro inhibitors
Su et al. Reviewing HIV-1 Gag mutations in protease inhibitors resistance: insights for possible novel Gag inhibitor designs
Wang et al. Broad-spectrum coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus diseases
Zanella et al. Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection
Charpentier et al. Resistance to HIV integrase inhibitors: about R263K and E157Q mutations
Lai Small molecule HIV-1 attachment inhibitors: discovery, mode of action and structural basis of inhibition
Ginex et al. Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
Wang et al. Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD
Kim et al. Geraniin inhibits the entry of SARS-CoV-2 by blocking the interaction between spike protein RBD and human ACE2 receptor
Yuan et al. Screening of an FDA-approved drug library with a two-tier system identifies an entry inhibitor of severe fever with thrombocytopenia syndrome virus
Lee et al. Foamy virus assembly with emphasis on pol encapsidation
Khan et al. Impact of the double mutants on spike protein of SARS-CoV-2 B. 1.617 lineage on the human ACE2 receptor binding: A structural insight
Yu et al. Computational simulation of HIV protease inhibitors to the main protease (Mpro) of SARS-CoV-2: Implications for COVID-19 drugs design
Borisevich et al. Simulation of Molecular Dynamics of SARS-CoV-2 S-Protein in the Presence of Multiple Arbidol Molecules: Interactions and Binding Mode Insights
Lapaillerie et al. In silico, in vitro and in cellulo models for monitoring SARS-CoV-2 Spike/Human ACE2 complex, viral entry and cell fusion
Panya et al. A synthetic bioactive peptide derived from the asian medicinal plant Acacia Catechu binds to dengue virus and inhibits cell entry
Elzupir Molecular docking and dynamics investigations for identifying potential inhibitors of the 3-chymotrypsin-like protease of SARS-CoV-2: repurposing of approved pyrimidonic pharmaceuticals for COVID-19 treatment
Kim et al. Mulberrofuran G, a mulberry component, prevents SARS-CoV-2 infection by blocking the interaction between SARS-CoV-2 spike protein S1 receptor-binding domain and human angiotensin-converting enzyme 2 receptor
Iannone et al. Emerging pharmacological treatments for migraine in the pediatric population
Eweas et al. Virtual screening of repurposed drugs as potential spike protein inhibitors of different SARS-CoV-2 variants: Molecular Docking Study
Venkatachalam et al. Understanding drug resistance of wild-type and L38HL insertion mutant of HIV-1 C protease to saquinavir
Ciftci et al. Identification of new L-heptanoylphosphatidyl inositol pentakisphosphate derivatives targeting the interaction with HIV-1 gag by molecular modelling studies